Tapojyoti Sanyal

Tapojyoti Sanyal

Auto-generated profile, based on publicly available information

Tapojyoti Sanyal

Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
MMMurali K. Mamidi
Murali K. Mamidi
SSSutapa Sinha
Sutapa Sinha
MMMariana T. Mendez
Mariana T. Mendez
TSTapojyoti Sanyal
Tapojyoti Sanyal
HMHasan Mahmud
Hasan Mahmud
AGAsish Ghosh
Asish Ghosh
Purpose: Although the B-cell receptor (BCR) signal plays a critical role in chronic lymphocytic leukemia (CLL) cell survival and a target of current therapies (ibrutinib targets Bruton’s tyrosine kinase; idelalisib targets PI3Kδ), contribution of the cytokine-driven JAK2 pathway to the “CLL cell-survival signaling network” is largely undefined. Experimental Design: Patients with CLL were enrolled to investigate expression/activation of JAK2 and acylglycerol kinase (AGK), and their functional implication in primary CLL cell survival. A series of biochemical and molecular biology assays were employed to uncover the underlying mechanism. Results: We detected that compared with normal B cells, CLL cells aberrantly express constitutively active JAK2. Mechanistically, HSP90 forms a chaperoning complex with JAK2, resulting in its aberrant accumulation in CLL cells. We also discovered aberrant upregulation of a novel mitochondrial lipid kinase, AGK, which remains complexed with HSP90 in CLL cells activating JAK2. Although AGK is typically mitochondrial, we detected its nuclear localization in association with JAK2 in some CLL cells. Functionally, JAK2 phosphorylates its noncanonical substrate, histone H3(Y41), but not STAT3, activating transcription of diverse sets of genes in a patient-specific manner. Additionally, JAK2 activates the BCR signal in CLL cells via LYN/Bruton’s tyrosine kinase axis. Targeted inhibition of JAK2 as monotherapy, or in combination with the BCR inhibitors or venetoclax (a BCL2 inhibitor), induced apoptosis synergistically in CLL cells. Conclusions: These findings suggest that aberrantly expressed AGK activates JAK2, independent of cytokine, leading to activation of diverse sets of gene transcription in CLL cells. Combined targeting of JAK2 and BCR signals or BCL2 may be effective in some patients with CLL.

3 February 2025
Verified
Other
Open access
MMMurali K. Mamidi
Murali K. Mamidi
SSSutapa Sinha
Sutapa Sinha
MMMariana T. Mendez
Mariana T. Mendez
TSTapojyoti Sanyal
Tapojyoti Sanyal
HMHasan Mahmud
Hasan Mahmud
AGAsish Ghosh
Asish Ghosh
Purpose:Although the B-cell receptor (BCR) signal plays a critical role in chronic lymphocytic leukemia (CLL) cell survival and a target of current therapies (ibrutinib targets Bruton’s tyrosine kinase; idelalisib targets PI3Kδ), contribution of the cytokine-driven JAK2 pathway to the “CLL cell-survival signaling network” is largely undefined.Experimental Design:Patients with CLL were enrolled to investigate expression/activation of JAK2 and acylglycerol kinase (AGK), and their functional implication in primary CLL cell survival. A series of biochemical and molecular biology assays were employed to uncover the underlying mechanism.Results:We detected that compared with normal B cells, CLL cells aberrantly express constitutively active JAK2. Mechanistically, HSP90 forms a chaperoning complex with JAK2, resulting in its aberrant accumulation in CLL cells. We also discovered aberrant upregulation of a novel mitochondrial lipid kinase, AGK, which remains complexed with HSP90 in CLL cells activating JAK2. Although AGK is typically mitochondrial, we detected its nuclear localization in association with JAK2 in some CLL cells. Functionally, JAK2 phosphorylates its noncanonical substrate, histone H3(Y41), but not STAT3, activating transcription of diverse sets of genes in a patient-specific manner. Additionally, JAK2 activates the BCR signal in CLL cells via LYN/Bruton’s tyrosine kinase axis. Targeted inhibition of JAK2 as monotherapy, or in combination with the BCR inhibitors or venetoclax (a BCL2 inhibitor), induced apoptosis synergistically in CLL cells.Conclusions:These findings suggest that aberrantly expressed AGK activates JAK2, independent of cytokine, leading to activation of diverse sets of gene transcription in CLL cells. Combined targeting of JAK2 and BCR signals or BCL2 may be effective in some patients with CLL.

3 February 2025
Verified
Other
Open access
PDF file
MMMurali K. Mamidi
Murali K. Mamidi
SSSutapa Sinha
Sutapa Sinha
MMMariana T. Mendez
Mariana T. Mendez
TSTapojyoti Sanyal
Tapojyoti Sanyal
HMHasan Mahmud
Hasan Mahmud
AGAsish Ghosh
Asish Ghosh
Supplementary Figure S5. JAK2 is not localized in mitochondria.


3 February 2025
Verified
Other
Open access
MMMurali K. Mamidi
Murali K. Mamidi
SSSutapa Sinha
Sutapa Sinha
MMMariana T. Mendez
Mariana T. Mendez
TSTapojyoti Sanyal
Tapojyoti Sanyal
HMHasan Mahmud
Hasan Mahmud
AGAsish Ghosh
Asish Ghosh
Supplementary Table S4. Target genes of the Erk1/2 MAPK pathway.

3 February 2025
Verified
Other
Open access
PDF file
MMMurali K. Mamidi
Murali K. Mamidi
SSSutapa Sinha
Sutapa Sinha
MMMariana T. Mendez
Mariana T. Mendez
TSTapojyoti Sanyal
Tapojyoti Sanyal
HMHasan Mahmud
Hasan Mahmud
AGAsish Ghosh
Asish Ghosh
Supplementary Table S1. CLL Patients’ Prognostic Characteristics.